Monday, May 01, 2017 11:32:44 AM
2Q’18
? CTL-019 treatment mainly in relapsed/refractory patients with poor prognosis:
10% B-ALL patients and 30% DLBCL patients
? Max 20% penetration of the ALL market in Europe and 30% in US; max 15%
penetration of the DLBCL market in Europe and 25% in US by 2025
? Price for single treatment: $600,000
? OXB receives 4% royalties
We estimate that Novartis will achieve sales of $2.05bn per annum from CTL-019 by
2025. OXB could, therefore, receive a total of $82.0m in royalties per annum, in
addition to manufacturing revenue.
HTTP://www.hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-documents/31.03.17-delivering-commercial-gene-therapy-vector.pdf
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM